复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

未开盘 04-30 16:08:06

16.320

-0.460

-2.74%

最高17.000	最低15.820	成交量44.61万
今开16.940	昨收16.780	日振幅7.03%
总市值88.70亿	流通市值26.67亿	总股本5.43亿
成交额730.48万	换手率0.27%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":16.32,"timestamp":1714464486029,"preClose":16.78,"halted":0,"volume":446100,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.0850843,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.46,"latestTime":"04-30 16:08:06","open":16.94,"high":17,"low":15.82,"amount":7304763,"amplitude":0.070322,"askPrice":16.32,"askSize":300,"bidPrice":16.22,"bidSize":900,"shortable":0,"etf":0,"ttmEps":1.07968049568544,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714613400000},"adr":0,"listingDate":1569340800000,"adjPreClose":16.78,"openAndCloseTimeList":[[1714440600000,1714449600000],[1714453200000,1714464000000]],"volumeRatio":0.8112089033196997,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2431785167","title":"复宏汉霖曲妥珠单抗获美国FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2431785167","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2431785167?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:09","pubTimestamp":1714392540,"startTime":"0","endTime":"0","summary":"汉曲优是在中国、欧盟、美国获批的\"中国籍\"单抗生物类似药，此前已于2020年7月及8月先后获得欧盟委员会与中国国家药监局批准上市。复宏汉霖执行董事、首席执行官兼首席财务官朱俊先生表示，汉曲优是复宏汉霖严格按照中国、欧盟和美国等生物类似药法规自主研发的曲妥珠单抗，也是公司首个通过FDA批准在美国开展商业化的产品。曲妥珠单抗正是治疗HER2阳性乳腺癌和胃癌的基石类药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4399761_ZH99761_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431888205","title":"复宏汉霖(02696.HK)首季营业收入按年增长35.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431888205","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431888205?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:36","pubTimestamp":1714379760,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布，首季实现营业收入约13.49亿元人民币(下同)，按年增长35.5%。当中，汉曲优(注射液曲妥珠单抗，欧洲商品名：Zercepac，美国商品名：HERCESSI)实现中国境内销售收入约6.71亿元；汉斯状(斯鲁利单抗注射液)实现中国境内销售收入约3.34亿元。(jl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345952/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431884928","title":"复宏汉霖(02696)第一季度实现营业收入约13.49亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431884928","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431884928?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:34","pubTimestamp":1714379687,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696)发布公告，2024年第一季度，集团把握既有的先发优势，全面推...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_36.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_36.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114169.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431007209","title":"复宏汉霖04月29日获主力加仓122万元 环比增加1642.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431007209","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431007209?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:16","pubTimestamp":1714378572,"startTime":"0","endTime":"0","summary":"04月29日, 复宏汉霖股价涨1.70%，报收16.78元，成交金额1144万元，换手率0.42%，振幅6.67%，量比1.22。复宏汉霖今日主力资金净流入122万元，连续7日净流入，上一交易日主力净流入7万元，今日环比增加1642.86%。该股近5个交易日上涨11.27%，主力资金累计净流入561万元；近20日主力资金累计净流入1488万元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042916165587be2fbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042916165587be2fbd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430052716","title":"2023年国产PD-1销售成绩单：百济超5亿美元，复宏汉霖增超两倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2430052716","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430052716?lang=zh_cn&edition=full","pubTime":"2024-04-28 21:16","pubTimestamp":1714310160,"startTime":"0","endTime":"0","summary":"近日，跨国药企默沙东披露的2024年第一季度财报显示，明星PD-1肿瘤药Keytruda贡献69亿美元收入，同比增长20%。随着2023年财报进入末尾，国内各家PD-1肿瘤药的销售情况也相继公布。君实生物PD-1肿瘤药的产销量情况 来源：2023年财报君实生物拥有国内首个获批的PD-1单抗特瑞普利单抗，2023年，期销量上升23.5%达到129.96万支，销售收入约9亿元，同比增长约25%。在国产PD-1四小龙中，君实生物和百济神州的PD-1已在美国获批，成为行业标志事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404282117488b5dfdf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404282117488b5dfdf8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430614220","title":"复宏汉霖曲妥珠单抗获FDA批准上市、翰森制药引进荃信生物一款自免单抗、一款国产PDE4抑制剂申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2430614220","media":"医药经济报","top":-1,"share":"https://www.laohu8.com/m/news/2430614220?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:17","pubTimestamp":1714130264,"startTime":"0","endTime":"0","summary":"复宏汉霖曲妥珠单抗获FDA批准上市4月26日，美国FDA批准复宏汉霖曲妥珠单抗生物类似药上市，用于辅助治疗HER2过表达的早期乳腺癌、HER2过表达的转移性乳腺癌，以及HER2过表达的转移性胃腺癌或胃食管交界处腺癌。一款国产PDE4抑制剂申报上市近日，据CDE网站显示，和美药业的莫米司特申报上市。严重TEAEs的发生率与剂量有关，60mg组为3.3%，45mg组和安慰剂组均为0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261926128b570336&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261926128b570336&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430643210","title":"复宏汉霖曲妥珠单抗生物类似药在美国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2430643210","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430643210?lang=zh_cn&edition=full","pubTime":"2024-04-26 14:08","pubTimestamp":1714111700,"startTime":"0","endTime":"0","summary":"南方财经4月26日，复宏汉霖宣布，该公司合作伙伴Accord公司（Intas美国子公司）于近日收到美国FDA通知，由复宏汉霖自主研发、生产的曲妥珠单抗生物类似药（HLX02，中国商品名为汉曲优）获美国批准上市，用于辅助治疗人表皮生长因子受体-2（HER2）过表达的乳腺癌、HER2过表达的转移性乳腺癌，以及HER2过表达的转移性胃腺癌或胃食管交界腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404263061125887.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430151492","title":"复宏汉霖：HLX02获美国FDA批准用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2430151492","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430151492?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:31","pubTimestamp":1714105907,"startTime":"0","endTime":"0","summary":"复宏汉霖港交所公告，HLX02（曲妥珠单抗，美国商品名：HERCESSITM）获美国食品药品管理局(FDA)批准用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042612315287b1dbd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042612315287b1dbd0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430213967","title":"复宏汉霖(02696.HK)：汉曲优获FDA批准用于乳腺癌辅助治疗等","url":"https://stock-news.laohu8.com/highlight/detail?id=2430213967","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430213967?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:21","pubTimestamp":1714105260,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布，HLX02(汉曲优)获美国食品药品管理局FDA批准用于辅助治疗HER2过表达乳腺癌；治疗HER2过表达转移性乳腺癌；及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌，其于美国获批的商品名为HERCESSI。据此，HLX02成为公司首个获FDA批准于美国上市的产品。该药是公司按照中国、欧盟和美国生物类似药指导原则自主开发并获中欧美三地批准的单抗生物类似药，用于HER2阳性的乳腺癌辅助治疗、HER2阳性的乳腺癌及胃癌治疗。(ha/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200928110330279_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200928110330279_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345384/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430745427","title":"复宏汉霖04月25日主力资金流入68万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2430745427","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430745427?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:15","pubTimestamp":1714032914,"startTime":"0","endTime":"0","summary":"04月25日, 复宏汉霖股价涨4.08%，报收16.34元，成交金额751万元，换手率0.29%，振幅6.88%，量比1.02。复宏汉霖今日主力资金净流入68万元，连续5日净流入，上一交易日主力净流入218万元，今日环比减少68.81%。该股近5个交易日上涨11.46%，主力资金累计净流入902万元；近20日主力资金累计净流入1339万元，其中净流入天数为13日。该股主力净额占比0.03%，港股市场排名136/2629。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516153687ae3b4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042516153687ae3b4f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430408584","title":"万千气象看上海 |创新药物已出海超40国，复宏汉霖透露国际化创新五点秘诀｜寻找中国经济新动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2430408584","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2430408584?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:22","pubTimestamp":1713946933,"startTime":"0","endTime":"0","summary":"同时，这也是复宏汉霖选择国际化创新之路的最新成果。复宏汉霖由华裔科学家刘世高和姜伟东联合创立。复宏汉霖的生产基地是国内最先获得海外不同监管机构认可的基地。其美国上市许可申请已获得美国FDA受理。目前，复宏汉霖也于泰国、新加坡、马来西亚等国家递交了产品上市许可申请。截至目前，H药对外授权已覆盖美国、欧洲、东南亚、中东和北非等70多个国家和地区。究其原因，复宏汉霖的PD-1单抗是差异化发展的典型案例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042416232287a9e00f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042416232287a9e00f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429816356","title":"复宏汉霖(02696)：HLX6018在健康受试者中开展的1期临床研究于中国境内完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2429816356","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429816356?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:51","pubTimestamp":1713862281,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，HLX6018在健康受试者中开展的1期临床研究于中国境内完成首例受试者给药。据悉，本研究为一项随机、双盲、安慰剂对照、单次给药、剂量递增的1期临床研究，旨在评估HLX6018在健康受试者中的安全性、耐受性、药代动力学特征和免疫原性。HLX6018为该公司自主研发的创新型抗GARP/TGF-β1复合物单抗，拟用于纤维化相关疾病的治疗。2024年3月，HLX6018用于特发性肺纤维化治疗的临床试验申请获国家药品监督管理局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107515.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429163908","title":"复宏汉霖(02696.HK)HLX6018注射液临床研究完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2429163908","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429163908?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:51","pubTimestamp":1713862260,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布，近日HLX6018在健康受试者中开展的1期临床研究于中国境内完成首例受试者给药。该注射液为公司自主研发，拟用于纤维化相关疾病的治疗。(ha/k)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200928110330858_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344367/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2429570501","title":"复宏汉霖04月23日主力资金流入144万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2429570501","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429570501?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:15","pubTimestamp":1713860123,"startTime":"0","endTime":"0","summary":"04月23日，复宏汉霖股价收平报15.26元，成交金额641万元，换手率0.26%，振幅3.54%，量比1.25。复宏汉霖今日主力资金净流入144万元，连续3日净流入，上一交易日主力净流入452万元，今日环比减少68.14%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为63.64%，平均涨幅为2.91%。该股近5个交易日上涨4.95%，主力资金累计净流入616万元；近20日主力资金累计净流入983万元，其中净流入天数为11日。该股主力净额占比0.06%，港股市场排名76/2629。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316154387a530b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316154387a530b4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429117519","title":"复宏汉霖04月22日获主力加仓452万元 环比增加2278.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429117519","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429117519?lang=zh_cn&edition=full","pubTime":"2024-04-22 16:15","pubTimestamp":1713773737,"startTime":"0","endTime":"0","summary":"04月22日, 复宏汉霖股价涨2.97%，报收15.26元，成交金额1137万元，换手率0.46%，振幅4.45%，量比3.43。复宏汉霖今日主力资金净流入452万元，上一交易日主力净流入19万元，今日环比增加2278.95%。该股近5个交易日上涨3.53%，主力资金累计净流入513万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入858万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221615598b4534ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221615598b4534ef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428864391","title":"复宏汉霖(02696)：HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2428864391","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2428864391?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:07","pubTimestamp":1713344847,"startTime":"0","endTime":"0","summary":"金吾财讯 | 复宏汉霖 宣布，近日，HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的临床试验申请获国家药品监督管理局批准。公司拟于条件具备后于中国境内开展该治疗方案的2期临床试验。HLX53是公司自主研发的创新型抗含Ig和ITIM结构域的T细胞免疫受体的Fc融合蛋白，拟用于治疗晚期实体瘤或淋巴瘤，于中国境内处于1期临床试验中。","market":"us","thumbnail":"https://static.szfiu.com/news/20200915/NjcwMDRkYTQ1ZjI5ZTlkNTkyYWIwMDM1OTZkMjUwMDIzNDA4Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjcwMDRkYTQ1ZjI5ZTlkNTkyYWIwMDM1OTZkMjUwMDIzNDA4Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935263","is_publish_highlight":false,"gpt_icon":0},{"id":"2428107399","title":"复宏汉霖(02696)：HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2428107399","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428107399?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:58","pubTimestamp":1713344307,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696)公布，近日，HLX53(抗TIGIT的Fc融合蛋白)(HLX...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_21.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_21.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103885.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428399869","title":"复星医药：子公司膦甲酸钠注射液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428399869","media":"证券时报","top":-1,"share":"https://www.laohu8.com/m/news/2428399869?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:42","pubTimestamp":1713343344,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，复星医药(600196)4月17日晚间公告，控股子公司复宏汉霖近日收到国家药监局关于同意其自主研发的HLX53（即抗TIGIT的Fc融合蛋白）联合汉斯状®（即斯鲁利单抗注射液）和汉贝泰®（即贝伐珠单抗注射液）一线治疗局部晚期或转移性肝细胞癌（HCC）开展临床试验的批准。控股子公司桂林南药的膦甲酸钠注射液的药品注册申请近日获国家药监局受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417164226878815b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417164226878815b7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428965243","title":"复星医药(600196.SH)：控股子公司复宏汉霖(02696)获药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2428965243","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428965243?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:40","pubTimestamp":1713343232,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(“复宏汉霖”)于近日收到国家药品监督管理局关于同意其自主研发的HLX53(即抗TIGIT的Fc融合蛋白)联合汉斯状®(即斯鲁利单抗注射液)和汉贝泰®(即贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌(HCC)(“该治疗方案”)开展临床试验的批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103865.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0695},{"period":"1month","weight":0.1982},{"period":"3month","weight":0.2179},{"period":"6month","weight":0.2554},{"period":"1year","weight":0.1493},{"period":"ytd","weight":0.1741}],"compareEarnings":[{"period":"1week","weight":0.0555},{"period":"1month","weight":0.0739},{"period":"3month","weight":0.1471},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.1071},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01（汉利康）、赫赛汀（曲妥珠单抗）生物类似药HLX02、修美乐（阿达木单抗）生物类似药HLX03和安维汀（贝伐珠单抗）生物类似药HLX04以及候选生物创新药，包括HLX06（一种新型VEGFR2抑制剂）、HLX07（一种EGFR抑制剂）、HLX10（一种新型PD-1抑制剂）、HLX20（一种新型PD-L1抑制剂）及HLX22（一种新型HER2抑制剂）等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.004462},{"month":2,"riseRate":0.6,"avgChangeRate":0.003175},{"month":3,"riseRate":0.4,"avgChangeRate":-0.070667},{"month":4,"riseRate":0.8,"avgChangeRate":0.127521},{"month":5,"riseRate":0.25,"avgChangeRate":-0.12475},{"month":6,"riseRate":0.5,"avgChangeRate":0.077913},{"month":7,"riseRate":0.5,"avgChangeRate":0.02822},{"month":8,"riseRate":0.25,"avgChangeRate":-0.071804},{"month":9,"riseRate":0,"avgChangeRate":-0.17846},{"month":10,"riseRate":0.4,"avgChangeRate":-0.013739},{"month":11,"riseRate":0.8,"avgChangeRate":0.086734},{"month":12,"riseRate":0.8,"avgChangeRate":-0.01905}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}